Innate Pharma S.A. (IPHA) vs Zura Bio (ZURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Innate Pharma S.A. (IPHA) has outperformed Zura Bio (ZURA) over the past year, losing 52.6% versus a loss of 74.4%. Innate Pharma S.A. is the larger company by market cap ($96.4 million vs $89.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IPHA | ZURA |
|---|---|---|
| Share price | $0.8634 | $0.9305 |
| Market cap | $96.44M | $89.63M |
| 1-day change | -8.14% | -2.30% |
| YTD return | -50.66% | -82.24% |
| 1-year return | -52.56% | -74.37% |
| 5-year return | -82.01% | — |
| EPS (TTM) | $-0.59 | $-1.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-68.65M |
| 52-week high | $2.71 | $7.44 |
| 52-week low | $0.829 | $0.919 |
| Distance from 52-week high | -68.14% | -87.49% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +826.57% | +759.75% |
| Average volume | 42.76K | 4.47M |
| Shares outstanding | 111.70M | 96.33M |
| Employees | 120 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IPHA has outperformed ZURA by 21.8 percentage points over the past year.
About Innate Pharma S.A.
IPHA stock →Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 120 employees
About Zura Bio
ZURA stock →Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees
IPHA vs ZURA FAQ
Which is bigger, Innate Pharma S.A. or Zura Bio?
Innate Pharma S.A. (IPHA) is larger, with a market capitalization of $96.44M compared with $89.63M for Zura Bio (ZURA).
Which stock has performed better over the past year, IPHA or ZURA?
IPHA returned -52.56% over the past 12 months, compared with -74.37% for ZURA (price return, excluding dividends). Past performance does not predict future results.
Are Innate Pharma S.A. and Zura Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.